Perspective: Research highlights at the Albert Einstein College of Medicine Center for AIDS Research: Approaches to control drug resistance in HIV: The role of increased polymerase fidelity

AIDS Research and Human Retroviruses

Volumn 12, Issue 11, 1996, Pages 959-963

  Prasad, Vinayaka R ^a   Drosopoulos, William C ^a   Hamburgh, Monica E ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DIDANOSINE; INTEGRASE; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; RNA DIRECTED DNA POLYMERASE; STAVUDINE; VIRUS PROTEIN; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RETROVIRUS; REVIEW; VIRUS MUTANT; VIRUS NUCLEOCAPSID; VIRUS REPLICATION;

EID: 0029738149     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1996.12.959     Document Type: Review

References (54)

1. Larder BA: Inhibitors of HIV reverse transcriptase as antiviral agents and drug resistance. In: Reverse Transcriptase (Skalka AM and Goff SP, eds.). Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1993, pp. 205-222.
2. Richman DD, Grimes JM, and Lagakos SW: Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. J AIDS 1990;3:743-746.
3. Richman DD: HIV drug resistance. AIDS Res Hum Retroviruses 1992;8:1065-1071.
4. Pandey VN, Kaushik N, Rege N, Sarafianos SG, Yadav PNS, and Modak MJ: Role of methionine 184 in human immunodeficiency virus type 1 reverse transcriptase in the polymerase function and fidelity of DNA synthesis. Biochemistry 1996;35:2168-2179.
5. Wainberg MA, Drosopoulos WC, Salomon H, Hsu M, Borkow G, Parniak MA, Gu Z, Song Q, Manne J, Islam S, Castriota G, and Prasad VR: Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science 1996;271:1282-1285.
6. Drosopoulos WC and Prasad VR: Increased polymerase fidelity of E89G, a nucleoside analog-resistant variant of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. J Virol 1996 (in press).
7. Coffin JM: HIV population dynamics in vivo: Implications for genetic variation, pathogenesis and therapy. Science 1995;267:483-489.
8. Johnson V: Nucleoside reverse transcriptase inhibitors and resistance of human immunodeficiency virus type 1. J Infect Dis 1995; 171:5140-5149. .
9. Pauwels R, Andries K, Debyser Z, Van Daele P, Schols D, Stoffels P, DeVreese K, Woestenborghs R, Vandamme AM, Janssen CGM, Anne J, Cauwenbergh G, Desmyter J, Heykants J, Janssen MAC, DeClercq E, and Janssen PAJ: Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of a-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proc Natl Acad Sci USA 1993;90:1711-1715.
10. Goldman ME, O'Brien JA, Ruffing TL, Nunberg JH, Schleif WA, Quintero JC, Siegl PK, Hoffman JM, Smith AM, and Emini EA: L-696,229 specifically inhibits human immunodeficiency virus type 1 reverse transcriptase and possesses antiviral activity in vitro. Antimicrob Agents Chemother 1992;36:1019-1023.
11. Romero DL, Busso M, Tan C-K, Reusser F, Palmer JR, Poppe SM, Aristoff PA, Downey KM, So AG, Resnick L, and Tarpley WG: Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. Proc Natl Acad Sci USA 1991;88:8806-8810.
12. Baba M, De Clercq E, Tanaka H, Ubasawa M, Takashima H, Sekiya K, Nitta I, Umezu H, Nakashima H, Mori S, Shigeta S, Walker RT, and Miyasaka T: Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase. Proc Natl Acad Sci USA 1991;88:2356-2360.
13. Richman D, Shin C-K, Lowy I, Rose J, Prodanavich P, Goff S, and Griffin J: Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc Natl Acad Sci USA 1991;88:11241-11245.
14. Richman DD, Havlir D, Corbeil J, Looney D, Ignacio C, Spector SA, Sullivan J, Cheeseman S, Barringer K, Pauletti, D, Shin C-K, Myers M, and Griffin J: Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapyl J Virol 1994;68:1660-1666.
15. Rice WG, Schaeffer CA, Graham L, Bu M, McDougal JS, Orloff SL, Villinger F, Young M, Oroszlan S, Fesen MR, Pommier Y, Mendeleyev J, and Kun E: The site of antiviral action of 3-nitrosobenzamide on the infectivity process of human immunodeficiency virus in human lymphocytes. Proc Natl Acad Sci USA 1993;90:9721-9724.
16. Rice WG, Supko JG, Malspeis L, Buckheit RW Jr, Clanton D, Bu M, Graham L, Schaeffer CA, Turpin JA, Domagala J, Gogliotti R, Bader JP, Halliday SM, Coren L, Sowder RC II, Arthur LO, and Henderson LE: Inhibitors of HIV nucleocapsid protein zinc fingers as candidates for the treatment of AIDS. Science 1995;270: 1194-1197.
17. Boucher CAB, O'Sullivan E, Mulder JW, Ramautarsing C, Kellam P, Darby G, Lange JMA, Goudsmit J, and Larder BA: Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis 1992;165:105-110.
18. St. Clair MH, Martin JL, Tudor-Williams G, Bach MC, Vavro CL, King DM, Kellam P, Kemp SD, and Larder BA: Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991;253:1557-1559.
19. Gu Z, Gao Q, Fang H, Salomon H, Parniak MA, Goldberg E, Cameron J, and Wainberg MA: Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase of human immunodeficiency virus resistant to 2′,3′-dideoxycytidine and 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1994;38: 275-280.
20. Larder BA, Darby G, and Richman DD: HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989;243:1731-1734.
21. Larder BA and Kemp SD: Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989;246:1155-1158.
22. Gu Z, Gao Q, Li X, Pamiak MA, and Wainberg MA: Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2′,3′-dideoxyinosine and 2′,3′dideoxycytidine. J Virol 1992;66:7128-7135.
23. Fitzgibbon JE, Howell RE, Haberzettl CA, Sperber SJ, Gocke DJ, and Dubin DT: Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2′,3′-dideoxycytidine. Antimicrob Agents Chemother 1992;36:153-157.
24. Zhang D, Caliendo AM, Eron JJ, DeVore KM, Kaplan JC, Hirsch MS, and D'Aquila RT: Resistance to 2′,3′-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1994;38:282-287.
25. Gao Q, Gu Z, Pamiak MA, Cameron J, Cammack N, Boucher C, and Wainberg MA: The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1993;37:1390-1392.
26. Tisdale M, Kemp SD, Parry NR, and Larder BA: Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 1993;90:5653-5656.
27. Schinazi RF, Lloyd Jr RM, Nguyen M, Cannon DL, McMillan A, Ilksoy N, Chu CK, Liotta-DC, Bazmi HZ, and Mellors JW: Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nuclcosides. Antimicrob Agents Chemother 1993;37:875-881.
28. Boucher CAB, Cammack N, Schipper P, Schurrman R, Rouse P, Wainberg MA, and Cameron JM: High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1993; 37:2231-2234.
29. Lacey SF and Larder BA: Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2′,3′-didehydro-2′,3′-dideoxythymidine in cell culture. Antimicrob Agents Chemother 1994;38:1428-1432.
30. Gu Z, Gao Q, Fang H, Parniak MA, Brenner BG, and Wainberg MA: Identification of novel mutations that confer drug resistance in the human immunodeficiency virus polymerase gene. Leukemia 1994;8:S166-S169.
31. Larder BA: 3′-Azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 1992;36:2664-2669.
32. Larder BA, Kemp SD, and Harrigan PR: Potential mechanism for sustained antiretroviral efficacy of 3TC-AZT combination therapy. Science 1995;269:696.
33. Larder BA: Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. J Gen Virol 1994;75:951-957.
34. Rose RE, Gong Y, Greytok JA, Bechtold CM, Terry BJ, Robinson BS, Alam M, Colonno RJ, and Lin P-F: Human immunodeficiency virus type 1 background plays a major role in development of resistance to protease inhibitors. Proc Natl Acad Sci USA 1996;93: 1648-1653.
35. Perelson AS, Neumann AU, Markowitz M, Leonard JM, and Ho DD: HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science 1996;271:1582-1586.
36. Chow Y-K, Hirsch MS, Merril DP, Bechtel LJ, Eron JJ, Kaplan JC, and D'Aquila RT: Use of evolutionary limitations of HIV-1 multidrug resistance optimize therapy. Nature (London) 1993; 361:650-654.
37. Emini EA, Graham DJ, Gotlib L, Condra JH, Byrnes VW, and Schleif WA: HIV and multidrug resistance. Nature (London) 1993; 364:679.
38. Larder BA, Kellam P, and Kemp SD: Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro. Nature (London) 1993;365:451-453.
39. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, and Steitz TA: Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992;256:1783-1790.
40. Jacobo-Molina A, Ding J, Nanni RG, Clark AD, Lu X, Tantillo C, Williams RL, Kamer G, Ferris AL, Clark P, Hizi A, Hughes SH, and Arnold E: Crystal structure of human immunodeficiency virus reverse transcriptase complexed with double stranded DNA at 3.0 A resolution shows bent DNA. Proc Natl Acad Sci USA 1993; 90:6320-6324.
41. Rodgers DW, Gamblin SJ, Harris BA, Ray S, Culp JS, Hellmig B, Woolf DJ, Debouck C, and Harrison SC: The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1995;92:1222-1226.
42. Ren J, Esnouf R, Hopkins A, Ross C, Jones Y, Stammers D, and Stuart D: The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: Lessons for inhibitor design. Structure 1995;3:915-926.
43. Esnouf R, Ren J, Ross C, Jones Y, Stammers D, and Stuart D: Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Struct Biol 1995;2:303-308.
44. Ding J, Das K, Tantillo C, Zhang W, Clark AD, Jessen S, Lu X, Hsiou Y, Jacobo-Molina A, Andries K, Pauwels R, Moereels H, Koymans L, Janssen PAJ, Smith RH, Kroeger Koepke M, Michejda CJ, Hughes SH, and Arnold EA: Structure of HIV-1 reverse transcriptase in a complex with the nonnucleoside inhibitor α-APA R 95845 at 2.8 Å resolution. Structure 1995;3:365-379.
45. Nanni RG, Ding J, Jacobo-Molina A, Hughes SH, and Arnold E: Review of HIV-1 reverse transcriptase three-dimensional structure: Implications for drug design. Perspect Drug Discov Design 1993; 129:129-150.
46. Prasad VR, Lowy I, De Los Santos T, Chiang L, and Goff SP: Isolation and characterization of a dideoxyguanosine triphosphate-resistant HIV-1 reverse transcriptase expressed in bacteria. Proc Natl Acad Sci USA 1991;88:11363-11367.
47. 89 residue in HIV-1 and HIV-2 reverse transcriptases: Effects on nucleoside analog-resistance. J Virol 1992;66:7568-7571.
48. Kew Y, Song Q, and Prasad V: Subunit selective mutagenesis of Glu89 residue in human immunodeficiency virus reverse transcriptase. J Biol Chem 1994;269:15331-15336.
49. Boyer PL, Tantillo C, Jacobo-Molina A, Nanni RG, Ding J, Arnold E, and Hughes SH: Sensitivity of wild-type human immunodeficiency virus type 1 reverse transcriptase to dideoxynucleotides depends on template length; the sensitivity of drug-resistant mutants does not. Proc Natl Acad Sci USA 1994;91:4882-4886.
50. Shirasaka T, Kavlick MF, Ueno T, Gao WY, Kojima E, Alcaide ML, Shokekijchai S, Roy BM, Arnold E, Yarchoan R, and Mitsuya H: Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci USA 1995;92:2398-2402.
51. Shafer RW, Kozal MJ, Winters MA, Iverson AKN, Katzenstein DA, Ragni MV, Meyer WA II, Gupta P, Rasheed S, Coombs R, Katzman M, Fiscus S, and Merigan TC: Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J Infect Dis 1994;169:722-729.
52. Spence RA, Kati WM, Anderson KS, and Johnson KA: Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 1995;267:988-993.
53. Pluda JM, Cooley TP, Montaner JSG, Shay LE, Reinhalter NE, Warthan SN, Ruedy J, Hirst HM, Vicary CA, Quinn JB, et al.: A phase I/II study of 2′-deoxy-3′-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection. J Infect Dis 1995;171:1438-1447.
54. Preston BD and Garvey N: Retroviral mutation and reverse transcriptase fidelity. Pharm Tech 1992;16:34-52.